Core Viewpoint - BWX Technologies (BWXT) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For BWX, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to upward pressure on its stock price [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2026, BWX is expected to earn $4.49 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 10.4% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988, indicating a strong performance potential [7][9]. - BWX's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting a strong likelihood of market-beating returns in the near term [10].

Core Insights - BWX Technologies, Inc. (BWXT) is expanding its nuclear medicine business to diversify revenue and reduce reliance on defense operations [1][4] Group 1: Nuclear Medicine Business - The company develops and manufactures radioisotopes and radiopharmaceuticals for medical imaging and cancer treatment, supporting healthcare providers [1] - A key focus is on producing medical isotopes for cancer detection and targeted radiation therapy, which involves specialized handling and regulatory compliance [2] - BWXT is investing in expanding isotope production capacity and improving supply chain efficiency to meet rising global demand for nuclear medicine [3][9] Group 2: Market Demand and Competition - The growing use of radiopharmaceuticals in diagnostics and cancer treatment is driving demand for reliable isotope supply [5] - Competitors in the field include Cardinal Health, Inc. and Telix Pharmaceuticals Limited, which also focus on radiopharmaceuticals for medical applications [5][6] Group 3: Financial Performance and Estimates - The Zacks Consensus Estimate predicts year-over-year earnings growth of 11.97% for 2026 and 13.51% for 2027 [7] - Current estimates for earnings per share are 0.89 for Q1 2026 and 4.49 for the full year 2026, with a year-over-year growth estimate of -2.20% for Q1 [8] Group 4: Stock Performance - BWXT is trading at a discount with a forward price-to-sales ratio of 5.05X compared to the industry average of 11.9X [10] - Over the past year, BWXT shares have increased by 111.4%, outperforming the industry growth of 36.1% [12] - BWXT currently holds a Zacks Rank 1 (Strong Buy), indicating strong market confidence [14]

Core Viewpoint - BWX Technologies has demonstrated strong performance in the nuclear energy sector, with a significant stock price increase and positive earnings growth, making it a notable investment opportunity. Financial Performance - BWX Technologies reported earnings of $1.08 per share and sales of $886 million for the fourth quarter, surpassing Wall Street estimates of $0.89 per share and $838 million in sales [2][3] - Earnings grew by 17% year-over-year, while sales increased by 19% [3] - The company announced a fourth-quarter dividend of $0.25 per share, followed by a planned dividend of $0.27 per share for shareholders on record as of March 11 [3] Future Outlook - BWX Technologies provided a strong full-year outlook, projecting earnings of $4.63 per share at the midpoint, exceeding analyst estimates of $4.62, with a sales outlook of $3.75 billion [4] - Analysts have raised their 2027 earnings estimates to $5.13 per share [5] Stock Performance - The stock has formed an early-stage consolidation pattern, with a buy point at $220.57, its all-time high [2] - BWX Technologies' shares surged by 55% in 2025, with a Relative Strength Rating of 93 and a Composite Rating of 96 out of a possible 99 [6] - The Accumulation/Distribution Rating of B- indicates that institutional buyers have been increasing their holdings over the past 13 weeks [7] Institutional Ownership - Institutions hold 56% of outstanding shares in BWX Technologies, with increased buying activity over the past three quarters [8]

INVESTOR BRIEFING March 2026 Aircraft carrier? Forward - Looking Statements Disclaimer BWX Technologies, Inc. ("BWXT") cautions that statements in this presentation that are forward-looking and provide other than historical information involve risks and uncertainties that may impact actual results and any future performance suggested in the forward-looking statements. The forward-looking statements in this presentation include, but are not limited to, statements relating to our 2026 and future strategic pri ...

Key Takeaways BWXT rides strong bookings and naval reactor contracts, backlog hit $7.3B at end-2025, up 50% year over year.WWD expects fiscal 2026 sales to rise 14% to 18%, led by Aerospace growth and solid Industrial demand.TDG benefits from strong potential Pentagon demand as U.S. defense spending may reach $1.5T by 2027.The defense equipment industry remains resilient, supported by rising defense spending and strategic mergers and acquisitions that improve operational scale, diversify product offerings a ...

Core Insights - Kinectrics has been selected as the design and fabrication partner for the UKAEA-Eni H3AT Tritium Loop Facility, which is anticipated to be the largest and most advanced tritium fuel cycle facility globally by 2030 [1][9] Company Overview - Kinectrics, a division of BWX Technologies Inc., specializes in lifecycle management services for the electricity industry, with expertise in engineering, inspection, and certification [10] - The company has extensive experience in tritium, a crucial fuel for future fusion power plants, and offers a vertically integrated delivery model along with in-house tritium infrastructure [2][10] Collaboration and Innovation - The partnership with UKAEA and Eni aims to enhance tritium technologies and address challenges in the design, manufacturing, testing, and delivery of fusion fuel cycles [3][4] - The collaboration is expected to accelerate the development of safe and commercially viable fusion energy, with a focus on the recovery and reuse of tritium [4][6] Government Support - The Canadian government has announced investments of up to $15 million to support Kinectrics' collaboration on the H3AT facility, highlighting the importance of Canadian nuclear expertise in the clean energy sector [5][8] Facility Details - The H3AT Tritium Loop Facility, located at Culham Campus in Oxfordshire, is projected to be completed by 2028, reinforcing the UK's position as a leader in fusion energy research [9]

Core Viewpoint - Nuclear energy is experiencing a resurgence, driven by increased demand from data centers and geopolitical factors affecting oil supply [1][2] Group 1: Industry Overview - Major countries investing in nuclear energy include the United States, Japan, South Korea, China, and India, focusing on expanding reactor fleets and reviving decommissioned reactors [1] - The volatility in oil prices, particularly due to potential disruptions in the Strait of Hormuz, is prompting more countries to consider nuclear power [2] Group 2: Cameco - Cameco is one of the largest uranium miners globally, responsible for 15% of the world's uranium production last year, operating the largest high-grade uranium mine at McArthur River [4][5] - The company reported a revenue of $3.4 billion, an 11% increase over 2024, with uranium prices rising by 34% over the past year [5] - Cameco maintains a net profit margin of 16.9% and a healthy debt-to-equity ratio of 0.14, indicating strong financial health [5] - In addition to mining, Cameco operates a uranium refinery and holds a 49% stake in Westinghouse, which designs and builds advanced nuclear reactors [6][7] Group 3: BWX Technologies - BWX Technologies has over 70 years of experience in building small-scale nuclear reactors and is developing small modular reactors (SMRs) [9][10] - The company generated revenue of $3.19 billion last year, an 18% increase over 2024, with earnings per share growing by 20% [12] - BWX has a strong net margin of 10.3% and is considered a safer investment in the SMR space compared to smaller, pure-play companies [11][13] Group 4: Constellation Energy - Constellation Energy is the largest producer of nuclear power in the U.S., operating 21 of the 94 nuclear reactors that generate 20% of the country's electricity [15] - The company saw an 8% revenue increase for 2025 compared to 2024, with adjusted operating EPS also growing by 8% [15] - Constellation maintains a net margin of 9.1% and has announced a 10% increase in its dividend per share, with another planned increase [16]

Core Insights - Global defense spending is undergoing a structural shift, focusing on nuclear propulsion, commercial nuclear power, and AI-driven law enforcement platforms, benefiting specialized defense contractors like BWX Technologies and Axon [1] Group 1: Defense Spending Trends - Governments are rethinking national security costs, leading to a genuine structural shift in defense spending [1] - Analysts are identifying companies positioned to capture long-term defense spending, not just immediate contracts [1] Group 2: Investment Opportunities - **iShares U.S. Aerospace & Defense ETF (ITA)**: - Holds 43 positions with $16 billion in net assets and an expense ratio of 0.38% - Year-to-date performance is up 11.2% and 61.9% over the past year [1] - **BWX Technologies (BWXT)**: - Reported fiscal 2025 revenue of $3.2 billion, up 18% year-over-year, with a backlog of $7.26 billion, a 50% increase [1] - Management projects 2026 revenue of approximately $3.75 billion and non-GAAP EPS of $4.55 to $4.70 [1] - **Axon Enterprise (AXON)**: - Q4 2025 revenue reached $796.7 million, up 38.5% year-over-year, with non-GAAP EPS of $2.15 [1] - Future contracted bookings are $14.4 billion, up 43% year-over-year, with a 2028 revenue target of approximately $6 billion [1] Group 3: Company Performance and Valuation - BWXT's stock trades around $195, up 103.6% over the past year, with a consensus target of $230.89 [1] - Axon's software business has margins exceeding 80%, with annual recurring revenue surpassing $1.35 billion and net revenue retention at 125% [1] - Axon faces risks including heavy stock-based compensation and a disclosed material weakness in internal controls [1]

Core Insights - BWX Technologies (BWXT) shares have increased by 101.9% over the past year, outperforming the Zacks Aerospace-Defense Equipment industry growth of 45.7%, the Aerospace sector's growth of 37.5%, and the S&P 500's rise of 26% [1][8]. Financial Performance - BWXT reported net sales of $3.20 billion for 2026, reflecting an 18.3% year-over-year increase, with adjusted earnings per share (EPS) rising by 20.4% to $4.01, driven by strong demand for nuclear components and services [5][8]. - The Zacks Consensus Estimate for BWXT's 2026 revenues indicates a solid improvement of 17.3% from the prior year, with earnings expected to improve by 11.5% [9]. Operational Initiatives - BWXT has opened a new Digital Center in Melbourne, FL, aimed at enhancing operational efficiency and decision-making across the enterprise [6][8]. - The Digital Center, covering 11,600 square feet, is part of BWXT's digital transformation initiatives to optimize workflows and improve customer responsiveness [6]. Valuation Metrics - BWXT shares are currently trading at a trailing 12-month Price/Book (P/B TTM) ratio of 14.53, which is below the industry average of 15.59 [13]. - The company's Return on Equity (ROE) stands at 30.94%, significantly higher than the industry average of 12.96%, indicating effective use of shareholders' equity [15]. Liquidity Position - BWXT has a current ratio of 2.32, indicating sufficient capital to meet short-term debt obligations [16]. Conclusion - BWX Technologies is well-positioned for long-term growth, supported by strong financial performance, rising revenue and earnings estimates, and steady demand for its nuclear components and services [20][21].

Core Insights - BWX Technologies, Inc. (BWXT) is crucial in the U.S. defense supply chain, particularly in naval nuclear propulsion, manufacturing nuclear components and fuel for nuclear-powered naval vessels [1][2] - The company’s expertise in nuclear manufacturing and its long-standing relationship with the U.S. government create significant barriers to entry for competitors, ensuring consistent demand for its services [4][8] Company Overview - BWXT produces precision reactor components and specialized nuclear fuel for the U.S. Naval Nuclear Propulsion Program, adhering to strict safety and performance standards [2][8] - The company also offers nuclear material processing and engineering services that support naval propulsion programs throughout their lifecycle [3][8] Industry Context - The demand for nuclear-powered naval platforms is rising, benefiting companies in the defense nuclear supply chain, including Huntington Ingalls Industries and Curtiss-Wright Corporation [5][6] - BWXT is investing in advanced nuclear technologies, such as microreactors and next-generation nuclear systems, to support future defense missions [4] Earnings Estimates - The Zacks Consensus Estimate for BWXT's earnings per share indicates year-over-year growth of 11.47% for 2026 and 13.05% for 2027 [7] - Current estimates for the upcoming quarters show a slight decrease in the current quarter but positive growth in subsequent periods [9] Stock Performance - BWXT is currently trading at a discount with a forward 12-month price-to-sales ratio of 4.72X compared to the industry average of 12.37X [10] - Over the past year, BWXT shares have increased by 99.8%, outperforming the industry growth of 45.3% [12]